Abstract
Cytosine arabinoside (Ara-C) is one of the key chemotherapy drugs comprising all stages combined protocols during long-term chemotherapy for children with acute leukemias, which demonstrated its efficacy and safety. Along with the progress of basic and clinical researches, in Ara-C clinical dose and treatment, prevention of adverse reactions, relationship between the drug metabolism and long-term clinical results, and new nucleoside drugs have achieved remarkable results. This paper on the above fields of research, progress and trends, briefly summarized as follows. Key words: Cytosine arabinoside; Leukemia; Metabolic key enzyme; Long-term efficacy; Adverse reaction
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
